Patients with schizophrenia, mood disorders, anxiety disorders have increased odds of COVID-19 mortality
However, risk for incident psychiatric morbidity was similar for those with negative SARS-CoV-2 test result and was higher with influenza
Relative risks for mortality significantly reduced for any SSRI, fluoxetine, and fluoxetine or fluvoxamine
Findings for county-level indicators of mental health in 2019 and county-level infection rates
Disproportionate increase in waiting-list registrations, liver transplants for alcoholic hepatitis associated with increasing alcohol sales
Increased levels of fatigue and dyspnea, decreased levels of physical activity reported; 63 percent showed at least mild cognitive impairment
Impairments in executive functioning, processing speed, category fluency, memory encoding, and recall seen months after hospitalization
Increase of 27.6 percent seen in cases of major depressive disorder globally; 25.6 percent increase reported in anxiety disorders
Risk for loss was 1.1 to 4.5 times higher among children of racial/ethnic minorities compared with non-Hispanic Whites
After controlling for lifetime comorbidities and adverse socioeconomic determinants of health, infection risk increased only for cannabis use disorder